title: [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
abstract: Therapeutic means for patients with disseminated painful bone metastases in breast cancer are strongly limited. There is a big need of an effective and well tolerated therapy. The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with bone metastases in breast cancer. 17 patients with painful bone metastases taking analgesics received one or more injections of 1295 MB9 rhenium-186 HEDP. In 59% of the patients the therapy resulted in a significant reduction of pain. The duration of pain relief partially hold on up to nine weeks. The main side effects of therapy were a short decrease of platelets and leucocytes and an increase of pain for 1-2 days. As conclusion we found out that therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy and radiation in patients with painful disseminated bone metastases in breast cancer.
authors.affiliation: Universitäts-Frauenklinik Bonn-Venusberg.
authors.forename: A E
authors.initials: AE
authors.lastname: Hauswirth
authors.forename: H
authors.initials: H
authors.lastname: Palmedo
authors.forename: C
authors.initials: C
authors.lastname: Dierke-Dzierzon
authors.forename: H J
authors.initials: HJ
authors.lastname: Biersack
authors.forename: D
authors.initials: D
authors.lastname: Krebs
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010147:Pain Measurement; D010166:Palliative Care; D011788:Quality of Life; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D012211:Rhenium / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011868:Radioisotopes; D012211:Rhenium; D012968:Etidronic Acid
vernacular_title: Schmerztherapie bei multiplen Knochenmetastasen bei Mammakarzinomen mit Rhenium-186 HEDP.